Mobia Medical (MOBI) Q3 2026 Earnings Call: Umsatz steigt um 73 %, Prognose angehoben
Der Umsatz von Mobia Medical (MOBI) stieg im dritten Quartal 2026 um 73 % auf 15,6 Millionen US-Dollar, die Bruttomarge erreichte 83,2 % und die Umsatzprognose für das Gesamtjahr wurde angehoben.
Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.
SektorMedizinische Geräte und Verbrauchsmaterialien